UPPFÆRT Blóðlækningar / krabbameinslækningar 2024
ESMO þing 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Þú ert að nota eldri útgáfu af vafranum þínum, þannig að sumir eiginleikar birtast kannski ekki rétt.
LÁGMARKSkröfur: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 bætir rPFS fyrir vönunarþolna blöðruhálskirtilskrabbameinssjúklinga með meinvörpum sem eru taxane-naive23 Okt 2023Niðurstöður PSMAfore rannsóknarinnar takmarkast af því að þær sýna ekki ávinning hvað varðar OS.
Skráðu þig fyrir miða eða bása
Kort af stað og hótel í kring
Munich - Holiday Inn Munich - Miðbær, Bæjaraland, Þýskaland Munich - Holiday Inn Munich - Miðbær, Bæjaraland, Þýskaland
Gerast áskrifandi